GlassScriptPhysician profile
Michael T Hood
NPI 1053396432
$14,170.59
in general payments reported to CMS, 2019-2025
53 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $3,448 · 2021: $2,240 · 2022: $1,709 · 2023: $1,687 · 2024: $1,078 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,253.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,109.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Minimed, INC. | $1,785.78 | 2019-2020 | |
| Abbvie INC. | $959.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $958.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $931.42 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $680.55 | 2019-2024 | Xarelto |
| Pfizer INC. | $677.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $672.76 | 2019-2025 | Jardiance |
| Amgen INC. | $450.87 | 2019-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $351.44 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $337.08 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $331.34 | 2019-2022 | |
| Lilly USA, LLC | $303.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $298.27 | 2019-2023 | |
| Mylan Specialty L.P. | $243.00 | 2019-2024 | Yupelri |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.